Pioglitazone for Idiopathic Gastroparesis (PIOGAS)
Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study)
Sponsor: Johns Hopkins University
Listed as NCT04300127, this EARLY_PHASE1 trial focuses on Gastroparesis and remains completed. Sponsored by Johns Hopkins University, it has been updated 10 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
May 2025 — Present [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Apr 2023 — Apr 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Apr 2022 — Apr 2023 [monthly]
Recruiting EARLY_PHASE1
-
May 2021 — Apr 2022 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2021 — May 2021 [monthly]
Recruiting EARLY_PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2020 — Oct 2020 [monthly]
Recruiting EARLY_PHASE1
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
For direct contact, visit the study record on ClinicalTrials.gov .